The current domestic treatment of chronic hepatitis C is still only interferon combined with ribavirin, the United States was the first to market by Gilead (Gilead) developed and produced sofibuvir, creating a new approach to oral drug therapy for hepatitis C. Subsequently, Bristol-Myers Squibb’s (BMS) new drug DCV, AbbVie’s new three-in-one drug, and Gilead’s combination have been marketed one by one, all of which have the advantage of mild adverse effects and SVR (durable virological response) of more than 90%, but at the same time, these drugs are also very expensive, for example, so far the SVR rate is higher for sofosbuvir combined with DCV, which costs up to RMB For example, sofosbuvir combined with DCV, which has a high SVR rate so far, costs up to RMB 1 million for 12 weeks, and the cheaper AbbVir triple drug costs over RMB 500,000. Some patients in China currently take the Indian version of sofosbuvir purchased online on their behalf, but they may not be aware that sofosbuvir in combination with ribavirin is not recommended for genotype 1 treatment, and nearly two-thirds of patients with hepatitis C in China are genotype 1, so oral drug therapy for hepatitis C still needs to be evaluated by a specialist. We also expect that oral hepatitis C drugs will be officially introduced into China as soon as possible, and that prices will be reduced to make them affordable for patients.